Last reviewed · How we verify
Dose Expansion3
At a glance
| Generic name | Dose Expansion3 |
|---|---|
| Sponsor | GeneQuantum Healthcare (Suzhou) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors (PHASE1, PHASE2)
- A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors (PHASE1)
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors (PHASE1, PHASE2)
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies (PHASE1)
- A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors (PHASE1, PHASE2)
- Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies (PHASE1, PHASE2)
- A Study of DB-1310 in Advanced/Metastatic Solid Tumors (PHASE1, PHASE2)
- First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dose Expansion3 CI brief — competitive landscape report
- Dose Expansion3 updates RSS · CI watch RSS
- GeneQuantum Healthcare (Suzhou) Co., Ltd. portfolio CI